Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

This phase 1b/2, multicenter, open‐label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL). Patients were treated with once‐daily ibrutinib 560 mg plus durvalumab 10 mg/kg every 2 weeks in 28‐day cycles in phase 1b with...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Alex F., Goy, Andre, Mehta, Amitkumar, Ramchandren, Radhakrishnan, Pagel, John M., Svoboda, Jakub, Guan, Shanhong, Hill, John S., Kwei, Kevin, Liu, Emily A., Phillips, Tycel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904508/
https://www.ncbi.nlm.nih.gov/pubmed/31621094
http://dx.doi.org/10.1002/ajh.25659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904508/
https://www.ncbi.nlm.nih.gov/pubmed/31621094
http://dx.doi.org/10.1002/ajh.25659

Ejemplares similares